hVIVO plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HVO.L research report →
Companywww.hvivo.com
hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide.
- CEO
- Yamin Mohammed Khan
- IPO
- 2012
- Employees
- 301
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $55.76M
- P/E
- -9.25
- P/S
- 1.16
- P/B
- 1.45
- EV/EBITDA
- -265.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -6.07%
- Op Margin
- -13.13%
- Net Margin
- -12.48%
- ROE
- -14.65%
- ROIC
- -11.14%
Growth & Income
- Revenue
- $46.77M · -25.43%
- Net Income
- $-5,992,999 · -156.26%
- EPS
- $-0.01 · -155.41%
- Op Income
- $-348,999
- FCF YoY
- -287.91%
Performance & Tape
- 52W High
- $17.25
- 52W Low
- $4.30
- 50D MA
- $7.53
- 200D MA
- $7.43
- Beta
- 1.69
- Avg Volume
- 3.05M
Get TickerSpark's AI analysis on HVO.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HVO.L Coverage
We haven't published any research on HVO.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HVO.L Report →